Chinook Therapeutics Obtains Worldwide Rights from AbbVie to Atrasentan with Plans to Develop for the Treatment of Kidney Diseases

January 17, 2020
Chinook Therapeutics Inc.

VANCOUVER, British Columbia–(BUSINESS WIRE)–Chinook Therapeutics, Inc., a biotechnology company focused on developing precision medicines for kidney diseases, today announced it has entered into a license agreement with AbbVie, a research-based global biopharmaceutical company, for worldwide, exclusive rights to atrasentan, an endothelin receptor antagonist. Chinook will assume all development and commercialization responsibilities for atrasentan globally. Chinook … Continue reading Chinook Therapeutics Obtains Worldwide Rights from AbbVie to Atrasentan with Plans to Develop for the Treatment of Kidney Diseases

InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress

January 16, 2020

VANCOUVER, January 16, 2020 /CNW/ — InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced that members of its senior scientific and clinical team will be attending the EB2020 World Congress, sponsored by the Dystrophic Epidermolysis Bullosa Research … Continue reading InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress

Shimadzu Medical Systems USA and NZ Technologies sign agreement to bring TIPSO AirPad Technology to the IXR Suite

January 14, 2020
NZ Technologies Inc.

TORRANCE, Calif., Jan. 13, 2020 /PRNewswire/ — Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation and a leader in diagnostic medical imaging systems, along with NZ Technologies of Vancouver Canada and developers of TIPSOTM technology, today announced that they have signed a one-year renewable agreement that allows Shimadzu to market and sell the innovative TIPSO AirPad® in the US healthcare market. … Continue reading Shimadzu Medical Systems USA and NZ Technologies sign agreement to bring TIPSO AirPad Technology to the IXR Suite

InMed Pharmaceuticals to Present at the Biotech Showcase Conference

January 13, 2020
InMed Pharmaceuticals Inc.

VANCOUVER, January 8, 2020 /CNW/ — InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced that Eric A. Adams, President & CEO will be presenting at the Biotech Showcase conference to be held at the Hilton San Francisco … Continue reading InMed Pharmaceuticals to Present at the Biotech Showcase Conference

InMed Announces Election of Directors

InMed Pharmaceuticals Inc.

Vancouver, BC – January 10, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today confirmed that at its annual general meeting of shareholders held on December 19, 2019 (the “Meeting”), all directors nominated as listed in the … Continue reading InMed Announces Election of Directors

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

Xenon Pharmaceuticals Inc.

Xenon’s Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020 Xenon Eligible for Milestone Payments Based on the Advancement of Partnered Programs Experienced Biotech Executive, Dr. Clarissa Desjardins, Joins Xenon’s Board of Directors BURNABY, British Columbia, Jan. 13, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), … Continue reading Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

Onestep Laboratories developed QuickRedTM (the first) small molecular Near Infrared nucleus stain for living cell imaging

January 9, 2020
Onestep Laboratories Inc.

The nucleus is a highly specialized organelle that serves as the information processing and administrative center of the cell. This organelle has two major functions: it stores the cell’s hereditary material, or DNA, and it coordinates the cell’s activities, which include growth, intermediary metabolism, protein synthesis, and reproduction (cell division). The nucleus is the information … Continue reading Onestep Laboratories developed QuickRedTM (the first) small molecular Near Infrared nucleus stain for living cell imaging

adMare BioInnovations and Accel-Rx Unite to Advance the Canadian Life Sciences Sector

adMare BioInnovations

Vancouver, Canada – January 9, 2020: With a shared vision to be a catalyst for Canadian life sciences leading the world, adMare BioInnovations, Canada’s Global Life Sciences Venture (adMare), and Accel-Rx, Canada’s Health Sciences Accelerator (Accel-Rx), announced today they are bringing their respective capabilities and resources together under adMare to create a world leading organization. … Continue reading adMare BioInnovations and Accel-Rx Unite to Advance the Canadian Life Sciences Sector

ASPECT BIOSYSTEMS ANNOUNCES US $20 MILLION SERIES A FINANCING TO ADVANCE ITS LEADING PLATFORM FOR 3D BIOPRINTING OF HUMAN TISSUE

Aspect Biosystems

VANCOUVER, British Columbia – January 9, 2020 – Aspect Biosystems (“Aspect”) (“the Company”), a biotechnology company pioneering microfluidic 3D bioprinting of human tissues, today announced a US $20 million Series A financing round.  Radical Ventures, a venture capital firm investing in entrepreneurs developing and applying deep tech to solve global problems and transform massive industries, … Continue reading ASPECT BIOSYSTEMS ANNOUNCES US $20 MILLION SERIES A FINANCING TO ADVANCE ITS LEADING PLATFORM FOR 3D BIOPRINTING OF HUMAN TISSUE

Global Health Sciences Fund (Quark Venture LP and GF Securities) Participate in Eyevensys’ USD $30 Million Series B Financing for Development of Ocular Platform

January 8, 2020
Quark Venture LP

Vancouver, January 8, 2020 – Quark Venture LP and GF Securities participated in the USD $30 million Series B financing round announced today by Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic and retinal diseases. The investment, made through the Global Health Sciences (GHS) Fund, is part of the Series … Continue reading Global Health Sciences Fund (Quark Venture LP and GF Securities) Participate in Eyevensys’ USD $30 Million Series B Financing for Development of Ocular Platform